Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 184

Results For "report"

1832 News Found

Syngene Q3 revenue up 13% to Rs. 585 Cr
News | January 22, 2021

Syngene Q3 revenue up 13% to Rs. 585 Cr

EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.

Commercial disinfectants equally as effective against new COVID strains: CBC
News | January 13, 2021

Commercial disinfectants equally as effective against new COVID strains: CBC

Viruses evolve into new strains when there is a change to their genetic composition.

Latest Stories

Glycomine completes enrollment in Phase 2b trial for rare genetic disorder

Zeto gains FDA nod for new outpatient EEG system promising faster brain health testing

Beacon raises $132M+ to bring AI-driven sleep diagnostics to masses

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging